InsiderTrades

Form 4 for TVTX Travere Therapeutics, Inc.

Accepted 2025-05-05 00:00:00 ET · period of report 2025-05-02 · accession 0001415889-25-012057 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-05-05 2025-05-02 TVTX Heerma Peter Chief COMMERCIAL Off M - OptEx — +4,920 130.0K +4% —
D 2025-05-05 2025-05-05 TVTX Heerma Peter Chief COMMERCIAL Off S - Sale+OE $21.05 -1,771 128.2K -1% -$37.3K
D 2025-05-05 2025-05-02 TVTX Heerma Peter Chief COMMERCIAL Off M - OptEx $0.00 -4,920 4,920 -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-05-02 M A 4,920 — 129,986 D — — (F2) Each PSU represents a contingent right to receive one share of the common stock of the Issuer.
2 Common Common Stock 2025-05-05 S D 1,771 $21.05 128,215 D — —
3 Derivative Performance-based restricted stock units 2025-05-02 M D 4,920 $0.00 4,920 D — · — to — 4,920 Common Stock (F2) Each PSU represents a contingent right to receive one share of the common stock of the Issuer. (F1) On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved.